Theratechnologies (OTCMKTS:THERF) Given Hold Rating at Mackie

Mackie reiterated their hold rating on shares of Theratechnologies (OTCMKTS:THERF) in a research note issued to investors on Wednesday, TipRanks reports.

Separately, ValuEngine raised Theratechnologies from a hold rating to a buy rating in a research note on Thursday, August 1st.

Shares of Theratechnologies stock traded up $0.17 during trading on Wednesday, reaching $3.80. The company’s stock had a trading volume of 133,700 shares, compared to its average volume of 25,677. The business’s 50-day moving average price is $4.05 and its 200-day moving average price is $4.73. Theratechnologies has a 52 week low of $3.58 and a 52 week high of $7.29. The company has a current ratio of 2.69, a quick ratio of 2.19 and a debt-to-equity ratio of 1.70.

Theratechnologies (OTCMKTS:THERF) last posted its quarterly earnings results on Thursday, July 11th. The company reported ($0.04) EPS for the quarter. The company had revenue of $15.61 million during the quarter. Theratechnologies had a negative net margin of 11.57% and a negative return on equity of 14.31%.

Theratechnologies Company Profile

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

See Also: How to interpret the current ratio

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.